This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Date and time:

06.09.24 at 08:00-09:00 CEST



Welcome and introduction

Uncovering the foundational root cause(s) of MASLD/MASH and its cardiometabolic correlations

A holistic approach to MASH management: Linking metabolic dysfunction to patients’ long-term outcome(s)

Deciphering the relationship between MASH resolution and long-term clinical benefits in people with MASH

Panel discussion and audience Q&A

Closing remarks and wrap up


Giorgio Sesti

University of Rome, Rome, Italy

Giorgio Sesti M.D. is Full Professor of Internal Medicine at the Sapienza University of Rome.

In 1983, Prof. Sesti received his medical degree with honours from the Sapienza University of Rome, and, in 1986, his Endocrinology Specialty Degree from the University of Rome Tor Vergata.


From 1987 to 1999, he worked at the Department of Internal Medicine of the University of Rome Tor Vergata  as an Assistant Professor, and from 1999 to 2000 as an Associate Professor of Internal Medicine at the same Institution.


His major research interests are the pathophysiology and treatment of obesity, metabolic syndrome, type 2 diabetes, MAFLD, and related traits. He was Principal Investigator in 50 Multicenter International Clinical Trials on new treatment of type 2 diabetes, dyslipidemia and related complications.


Prof. Sesti was awarded the Schering Award from Italian Endocrine Society for investigator under 40 years in 1999, the SID-Alcmeone Award, the Italian Diabetes Society’s highest scientific award for Investigator under 45 years which recognizes outstanding scientific achievement in the diabetes field in 2002, the SID-Celso Medal for Scientific Achievement Award, the Italian Diabetes Society’s highest scientific award for Investigator who has made significant, long-term contributions to diabetes research, education and awareness in 2010.  


He has served the Italian Diabetes Society as President from 2016 to 2018, and is currently the President of the Italian Society of Internal Medicine. He is Associate Editor of Diabetes Research and Clinical Practice, the official journal of the International Diabetes Federation.


Prof. Sesti has authored 402 publications in peer-reviewed journals with a publication record of 205733 citations and a Hirsch (H) factor of 70 (Scopus). 

Read full bio

Pam Taub

UC San Diego, San Diego, US

Pam R. Taub, MD, FACC, FASPC is a board-certified cardiologist and internationally recognized expert in cardiometabolic disease.


She is the founding director of the Step Family Foundation Cardiac Rehabilitation and Wellness Center and Professor of Medicine at UC San Diego. Dr. Taub was responsible for all aspects of creating the center, which provides a comprehensive cardiac rehabilitation program for patients with established heart disease.   


Her clinical practice focuses on preventive cardiology, lipidology, as well as women's cardiovascular health. Her research focuses on assessing the impact of behavioral, technological, and pharmacological interventions on cardiometabolic disease. Dr. Taub's is a federally funded researcher with funding from: the National Institutes of Health (Principal Investigator on R01 grant), Department of Defense, Department of Homeland Security and American Heart Association.   She is an experienced clinical trialist and serves on the executive committee for multiple international clinical trials focused on novel cardiovascular therapies.

Dr. Taub is widely published (with over 100 publications) and has authored high impact publications in top peer-reviewed journals including Cell Metabolism and the Journal of the American College of Cardiology that have made an impact on clinical practice.

Dr. Taub holds multiple leadership positions in professional societies, serving as a fellow and board member for the American Society of Preventive Cardiology.  She is a fellow and member of the American College of Cardiology Prevention of CV Disease Section Leadership Council. She also serves the Vice-Chair of the American Heart Association Council Women in Cardiology Committee.

Read full bio